Genovis AB (FRA:5GV) Current Deferred Revenue: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5GV Genovis AB FRA:5GV
92 GF Score
Price €1.73
GF Value €2.31
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genovis AB Current Deferred Revenue?

Genovis AB FRA:5GV -0.12% 92 Current Deferred Revenue is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:5GV with a GF Score™ of 92/100 and a GF Value™ of €2.31 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Genovis AB's current deferred revenue for the quarter that ended in Jun. 2026 was €0.00 Mil.

Genovis AB Current Deferred Revenue Related Terms

Genovis AB Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Genovis AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovis AB Current Deferred Revenue Chart

Genovis AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genovis AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:5GV
92GF Score
Genovis AB FRA:5GV
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.00 Mil mean?
Genovis AB (FRA:5GV) has a Current Deferred Revenue of €0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Genovis AB and its competitors.
Is Genovis AB's Current Deferred Revenue too high?
Genovis AB's current Current Deferred Revenue is €0.00 Mil. Overall, Genovis AB has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Current Deferred Revenue compare to VRTX and REGN?
Genovis AB's Current Deferred Revenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Genovis AB and its competitors. Genovis AB's current Current Deferred Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (FRA:5GV) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.31, compared to a current price of €1.73 — trading 24.9% below its estimated fair value. The current Current Deferred Revenue is €0.00 Mil. Genovis AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current Current Deferred Revenue is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovis AB (FRA:5GV) Overvalued in 2026?

Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued. The current stock price of €1.73 is trading 24.9% below its estimated GF Value™ of €2.31. GuruFocus considers Genovis AB to be Modestly Undervalued.

Key valuation signals for FRA:5GV:

  • Current Deferred Revenue: €0.00 Mil
  • GF Value™: €2.31 vs. price of €1.73 (24.9% below fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovis AB Business Description

Other Exchanges GENO:Sweden
Address Kavlinge, Box 4, Lund, SWE, SE-24421
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
92GF Score

Get the complete analysis for FRA:5GV

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.73
Price
€2.31
GF Value